Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial-Reference-Cited by-同舟云学术

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Published:2023-03 Issue:10379 Volume:401 Page:821-832
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Motzer Robert J,Russo Paul,Grünwald Viktor,Tomita Yoshihiko,Zurawski Bogdan,Parikh Omi,Buti Sebastiano,Barthélémy Philippe,Goh Jeffrey C,Ye Dingwei,Lingua Alejo,Lattouf Jean-Baptiste,Albigès Laurence,George Saby,Shuch Brian,Sosman Jeffrey,Staehler Michael,Vázquez Estévez Sergio,Simsek Burcin,Spiridigliozzi Julia,Chudnovsky Aleksander,Bex Axel

Funder

Bristol-Myers Squibb

Memorial Sloan Kettering Cancer Center

Publisher

Elsevier BV

Subject

General Medicine

Reference23 articles.

1. Adjuvant therapy options in renal cell carcinoma: where do we stand?;Martinez Chanza;Curr Treat Options Oncol,2019

2. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results;Motzer;Eur Urol,2018

3. Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: a trial-level meta-analysis;Harshman;Cancer,2018

4. Review of adjuvant therapies in renal cell carcinoma: evidence to date;Tacconi;OncoTargets Ther,2020

5. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy;Ravaud;N Engl J Med,2016

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of outcomes of radical and partial nephrectomy for sarcomatoid renal cell carcinoma: analysis of the national cancer database;World Journal of Urology;2024-09-06

2. Turning the tide: pembrolizumab’s triumph in adjuvant RCC therapy;Medical Oncology;2024-09-05

3. Verlängertes Gesamtüberleben unter adjuvanter Pembrolizumab-Therapie;InFo Hämatologie + Onkologie;2024-09

4. Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial;European Urology;2024-09

5. Contemporary Management of Renal Cell Carcinoma: A Review for General Practitioners in Oncology;Current Oncology;2024-08-22